Dowingtown, PA, United States of America

Jill M Giles-Komar

USPTO Granted Patents = 56 

 

 

Average Co-Inventor Count = 5.3

ph-index = 18

Forward Citations = 1,196(Granted Patents)

Forward Citations (Not Self Cited) = 1,176(Oct 12, 2025)


Inventors with similar research interests:


Location History:

  • Dowingtown, PA (US) (2010)
  • Berwyn, PA (US) (2010)
  • Downington, PA (US) (2012)
  • Radnor, PA (US) (2012 - 2013)
  • Spring House, PA (US) (2014 - 2018)
  • Downingtown, PA (US) (2005 - 2023)

Company Filing History:


Years Active: 2005-2024

Loading Chart...
Loading Chart...
Loading Chart...
56 patents (USPTO):Explore Patents

Title: **Jill M Giles-Komar: Innovator in Antibody Therapeutics**

Introduction

Jill M Giles-Komar, based in Downingtown, Pennsylvania, has made significant contributions to the field of biotechnology, particularly in the development of antibody therapies. With an impressive portfolio of 56 patents, Giles-Komar has been at the forefront of innovations that hold promise for the treatment of various diseases.

Latest Patents

Among her recent innovations, Giles-Komar has developed patents related to anti-IL-23 antibodies, which include isolated nucleic acids that encode these antibodies, as well as methods for their production and application in diagnostic and therapeutic settings. Additionally, her patent portfolio encompasses anti-CD3 antibodies and their uses, focusing on antibodies that specifically bind to CD3, PSMA, IL1RAP, CD33, and TMEFF2. These advancements represent cutting-edge approaches in immunotherapy, providing new avenues for treatment and diagnosis.

Career Highlights

Throughout her career, Jill M Giles-Komar has made impactful contributions while working with renowned companies in the biotechnology sector such as Janssen Biotech, Inc. and Centocor, Inc. Her work has not only resulted in a substantial number of patents but has also propelled forward the understanding and application of antibody-based therapies.

Collaborations

Giles-Komar has collaborated with prominent colleagues, including David M Knight and Bernard Scallon. These partnerships have enhanced her research capabilities and contributed to the successful development of innovative therapeutic strategies.

Conclusion

Jill M Giles-Komar stands out as an influential inventor in the realm of antibody therapeutics. Her extensive patent portfolio showcases her commitment to advancing medical science and improving patient outcomes through innovative therapies. Her work continues to inspire future developments in biotechnology, reflecting the ongoing need for innovation in healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…